What are the opening hours?

Monday 8am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Ametris

Pioneering the Digital Transformation of Clinical Research

08/20/2026

Whether you're interested in cross-industry collaboration on new insights involving digital health technologies or scaling decentralized patient trials, the Ametris Digital Data Summit (ADDS) offers vast scientific visibility in topics like physical activity measures, AI, digital health, gait and mobility, sleep monitoring, and more.

We are excited for our call for abstracts at our Scientific Poster Session at our Ametris Digital Data Summit (ADDS), taking place Feb. 8-10, 2027 in Atlanta. We invite you to submit an abstract describing your original research involving the use of digital health technologies (DHTs) - including wearables, sensors and/or eCOA. For select abstracts, we are also offering the opportunity to present a short oral presentation (5-7 minutes).

For more details on travel awards and to submit your abstract by October 30th, 2026. Submit your abstract here: https://hubs.la/Q04tLnlt0

08/11/2026

In the age of GLP1s, combining obesity research with Digital Health Technologies (DHTs)—like wearables—offers a path toward better outcomes and continuous real-world data.

Ametris leaders, Chief Scientific Officer, Christine Guo, and Director of DHT Solutions Strategy, Sylvain Zorman, emphasize, formal uptake will require regulator-friendly frameworks and fit-for-purpose algorithms.

Read the new article by Annabel Kartal Allen in Medical Device Network: https://hubs.la/Q04syC5P0

08/07/2026

Your endpoint strategy is your biggest trial risk, especially in progressive neuromuscular disease (NMD), where conventional endpoints are episodic and lack sensitivity to early and subtle changes. Continuous, digital assessments of function provide a more complete picture of progression and therapeutic efficacy, but they are only as good as the scientific expertise behind them.

Ametris delivers a suite of fit-for-purpose digital endpoints for NMD, including ALS and DMD, backed by an in-house team of data scientists, biostatisticians, clinical scientists, and engineers. We work alongside your team on digital biomarker development and validation, endpoint selection, biostatistical planning and analysis, and regulatory engagement — from early design through submission.

If your team doesn't have in-house DHT expertise, Ametris provides end-to-end support, so you can focus on developing life-changing therapies for the patients who need them most.

Explore our suite of digital endpoints for NMD: https://hubs.la/Q04skDl40

08/04/2026

📣 Call for Abstracts! 📣

We are excited to host a Scientific Poster Session during the fifth annual Ametris Digital Data Summit (ADDS), taking place Feb. 8-10 in Atlanta. We invite you to submit an abstract describing your original research involving the use of digital health technologies (DHTs) - including wearables, sensors and/or eCOA - no later than Friday, October 30th, 2026.

For more details on travel awards and to submit your abstract, visit: https://hubs.la/Q04rSVlw0

We look forward to seeing you February 8-10 in Atlanta, GA.

07/29/2026

In progressive neuromuscular diseases like ALS and Duchenne muscular dystrophy (DMD), capturing meaningful, continuous measures of function across the full disease trajectory - both ambulatory and non-ambulatory stages - can be notoriously complex.

Ametris delivers a suite of clinically validated regulatory-aligned digital endpoints designed specifically for neuromuscular disorder populations—out of the box. Coupled with our end-to-end scientific, clinical, and data operations support, we handle everything from endpoint design to submission, so biotech teams can focus on building evidence, not the infrastructure behind it.

💡Explore our fit-for-purpose digital measurement solutions for neuromuscular diseases: https://hubs.la/Q04rdfks0

07/27/2026

Last chance to register for tomorrow's Digital Health Monthly webinar:
Achieving Data Compatibility and Navigating Hardware Evolution Across Sensor Generations with Confidence

Long-term clinical protocols and multi-year epidemiological cohorts face the inevitable operational challenge of hardware obsolescence. During this live webinar, a panel of DHT experts will explore how strategic deployment of standardized post-processing methods, grounded in the DiMe V3+ framework, enables wearable device upgrades while maintaining data compatibility when raw data is consistently captured.

🗓️ Tuesday, July 28 @ 12-1PM EDT

Featured Speakers:
🔹Samuel R. LaMunion, PhD, LRS&C
🔹Grace Lee, PhD, Critical Path Institute
🔹Marie McCarthy, Novartis
🔹Benjamin Boudreaux, PhD, University of Alabama
🔹Christine Guo, PhD, Ametris

Secure your spot: https://hubs.la/Q04qT1Sd0

07/21/2026

As digital health technologies (DHTs) evolve, regulatory standards are shifting rapidly to keep pace with clinical research innovation. Navigating these changes is critical for biopharma leaders looking to build regulatory-ready solutions and achieve clinical success.

We're excited to share exclusive, on-demand videos from our ADDS 2026 conference featuring insights from regulators and regulatory experts from the U.S. Food and Drug Administration (FDA), the Critical Path Institute (C-Path), Eli Lilly, and more.

This curated session includes key presentations and an expert panel discussion focused on data-backed strategies for DHT validation and clinical adoption.

Watch now: https://hubs.la/Q04q8ydR0

07/07/2026

If a patient's AFib episode happens outside the clinic, does your trial capture it?

For conditions like heart failure, coronary artery disease, CKD, and obesity, episodic ECG monitoring leaves critical gaps — and those gaps can undermine your endpoints.

Ametris Senior Data Scientist Michael Pettinati, PhD breaks down the monitoring landscape and makes the case for continuous wearable assessment in AFib clinical research.

👉 Read: Monitoring Atrial Fibrillation in Clinical Research: The Case for Continuous Wearable Assessment
https://hubs.la/Q04nMyd90

07/06/2026

Cardiology experts discuss how continuous digital measures are transforming cardiovascular trials – from coronary artery disease, heart failure, and oncology trials, to live case studies and new research on physical activity and sleep.

Watch the new on-demand webinar on patient-centric cardiovascular endpoints: https://hubs.la/Q04nCJh50

06/29/2026

How comparable are physical behavior measurements across wearable actigraphy devices and models?

For researchers aggregating independent cohorts or harmonizing multi-year longitudinal data, that question is foundational — and now it has a reproducible, evidence-based answer.

A recent multi-year NIH and Ametris study published in Medicine & Science in Sports & Exercise establishes a verification framework for ensuring data continuity across actigraphy device generations. The result is a clear, replicable protocol researchers can apply to their own work.

Check out our newest blog article to explore key findings from study co-author Samuel R. LaMunion, PhD and watch his on-demand presentation from ADDS 2026: Device Comparability and Data Compatibility Across ActiGraph Generations.

Link in the comments ⬇️

Address

Pensacola, FL

Opening Hours

Monday	8am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+18503327900

Website

http://www.ametris.com/

Alerts

Be the first to know and let us send you an email when Ametris posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Ametris:

Want your business to be the top-listed Health & Beauty Business in Pensacola?